Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08).

ABSTRACT:

Background

This prospective observational study evaluated the real-world effectiveness of nivolumab monotherapy in previously treated advanced gastric cancer (GC). A preplanned 2-year final analysis was performed to confirm survival and tumor behavior with nivolumab monotherapy.

Patients and methods

The primary endpoint was overall survival (OS). The data regarding tumor size were prospectively collected and evaluated using the RECIST criteria. Exploratory analyses were performed for survival according to the tumor response and depth of response (DpR) in patients with measurable lesions who were receiving nivolumab monotherapy as third- or later-line therapy.

Results

In 487 patients, the median OS and progression-free survival (PFS) were 5.8 (95% CI 5.3-6.9) months an

SUBMITTER: Sunakawa Y 

PROVIDER: S-EPMC11299930 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature